These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6786318)

  • 21. Effects of sub-lethal concentrations of the antimicrobial agent propylene phenoxetol on the growth and extracellular enzymes of Propionibacterium acnes.
    Greenman J
    Microbios; 1984; 39(156):101-8. PubMed ID: 6231455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacterial resistance in French acne patients.
    Dumont-Wallon G; Moyse D; Blouin E; Dréno B
    Int J Dermatol; 2010 Mar; 49(3):283-8. PubMed ID: 20465665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [In vitro sensitivity of Corynebacterium acnes (Propionibacterium acnes) to meclocycline, clindamycin, erythromycin and neomycin].
    Lucca L; Vittadini G
    G Ital Chemioter; 1979; 26(1-2):203-6. PubMed ID: 554810
    [No Abstract]   [Full Text] [Related]  

  • 24. Nasal antibiotic-resistant Propionibacterium acnes carriage in acne vulgaris patients in Turkey.
    Ergin C; Ergin S; Kaleli I; Kaçar N; Sengül M; Erdoğan BS
    J Dermatol; 2006 Dec; 33(12):899-901. PubMed ID: 17169100
    [No Abstract]   [Full Text] [Related]  

  • 25. Topical antibiotics and topical antimicrobial agents in acne therapy.
    Leyden JJ; McGinley K; Mills OH; Kligman AM
    Acta Derm Venereol Suppl (Stockh); 1980; Suppl 89():75-82. PubMed ID: 6451130
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study.
    Dreno B; Foulc P; Reynaud A; Moyse D; Habert H; Richet H
    Eur J Dermatol; 2005; 15(3):152-5. PubMed ID: 15908296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-lipase activity of Kampo formulations, coptidis rhizoma and its alkaloids against Propionibacterium acnes.
    Higaki S; Nakamura M; Morohashi M; Hasegawa Y; Yamagishi T
    J Dermatol; 1996 May; 23(5):310-4. PubMed ID: 8675819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
    Ross JI; Snelling AM; Eady EA; Cove JH; Cunliffe WJ; Leyden JJ; Collignon P; Dréno B; Reynaud A; Fluhr J; Oshima S
    Br J Dermatol; 2001 Feb; 144(2):339-46. PubMed ID: 11251569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The influence of coptidis rhizoma to lipase activity of Propionibacterium acnes].
    Higaki S; Hasegawa Y; Morohashi M; Sakamoto K; Yamagishi T
    Nihon Hifuka Gakkai Zasshi; 1990 Jul; 100(8):883-6. PubMed ID: 2232295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resveratrol inhibition of Propionibacterium acnes.
    Docherty JJ; McEwen HA; Sweet TJ; Bailey E; Booth TD
    J Antimicrob Chemother; 2007 Jun; 59(6):1182-4. PubMed ID: 17449884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activity of topical agents against Propionibacterium acnes: an in vitro study of clinical isolates from a hospital in Shanghai, China.
    Ma Y; Zhang N; Wu S; Huang H; Cao Y
    Front Med; 2016 Dec; 10(4):517-521. PubMed ID: 27896620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetracycline and 13-cis-retinoic acid inhibit production and activity of granulocyte activating factor (GAF) from Propionibacterium acnes.
    Pulverer G; Ko HL; Beuth J; Roszkowski W
    Zentralbl Bakteriol; 1990 Aug; 273(3):362-8. PubMed ID: 1698375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MLST typing of antimicrobial-resistant Propionibacterium acnes isolates from patients with moderate to severe acne vulgaris.
    Giannopoulos L; Papaparaskevas J; Refene E; Daikos G; Stavrianeas N; Tsakris A
    Anaerobe; 2015 Feb; 31():50-4. PubMed ID: 25451716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic susceptibility of Propionibacterium acnes isolated from acne vulgaris in Korea.
    Song M; Seo SH; Ko HC; Oh CK; Kwon KS; Chang CL; Kim MB
    J Dermatol; 2011 Jul; 38(7):667-73. PubMed ID: 21352337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of topical erythromycin on aerobic and anaerobic surface flora.
    Bernstein JE; Shalita AR
    Acta Derm Venereol; 1980; 60(6):537-9. PubMed ID: 6162344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of pH on biomass, maximum specific growth rate and extracellular enzyme production by three species of cutaneous propionibacteria grown in continuous culture.
    Greenman J; Holland KT; Cunliffe WJ
    J Gen Microbiol; 1983 May; 129(5):1301-7. PubMed ID: 6311940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Myrtus communis extract enriched in myrtucummulones and ursolic acid reduces resistance of Propionibacterium acnes biofilms to antibiotics used in acne vulgaris.
    Feuillolay C; Pecastaings S; Le Gac C; Fiorini-Puybaret C; Luc J; Joulia P; Roques C
    Phytomedicine; 2016 Mar; 23(3):307-15. PubMed ID: 26969384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rhodomyrtone inhibits lipase production, biofilm formation, and disorganizes established biofilm in Propionibacterium acnes.
    Wunnoo S; Saising J; Voravuthikunchai SP
    Anaerobe; 2017 Feb; 43():61-68. PubMed ID: 27923605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combination of ellagic acid and tetracycline inhibits biofilm formation and the associated virulence of Propionibacterium acnes in vitro and in vivo.
    Sivasankar C; Maruthupandiyan S; Balamurugan K; James PB; Krishnan V; Pandian SK
    Biofouling; 2016; 32(4):397-410. PubMed ID: 26930280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of eight tetracyclines on growth and lipase formation of Staphylococcus aureus.
    Mates A
    Microbios; 1974; 10A SUPPL(41):105-10. PubMed ID: 4218293
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.